DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer

BACKGROUND: There is an increasing interest for Notch signalling pathway and particularly Delta-like ligand 4 (DLL4) as potential therapeutic target to improve outcome for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Using immunohistochemistry (IHC) and tissue microarray (TMA), we...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Cancer
Päätekijät: Drouillard, A, Puleo, F, Bachet, J B, Ouazzani, S, Calomme, A, Demetter, P, Verset, G, Van Laethem, J L, Maréchal, R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 2016
Aiheet:
Molecular Diagnostics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5104892/
https://ncbi.nlm.nih.gov/pubmed/27755532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.319
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia